Methods Of Reducing The Risk Of Cardiovascular Events In A Subject
Patent No. EP4056176 (titled "Methods Of Reducing The Risk Of Cardiovascular Events In A Subject") was filed by Amarin Pharmaceuticals Ireland on Apr 22, 2019. The application was issued on Apr 24, 2024.
Patent Summary
Compositions for reducing cardiovascular risk in patients with established cardiovascular disease or high cardiovascular risk, particularly those on statin therapy. The compositions contain ethyl EPA, a naturally occurring omega-3 fatty acid with cardiovascular protective effects, and are formulated to achieve a therapeutic dose of ethyl EPA while maintaining a controlled daily dose of ethyl EPA. The compositions can be administered orally, either as a single dose or in a sustained-release formulation, and have demonstrated cardiovascular benefits in patients on statin therapy, including reduced risk of cardiovascular events, including myocardial infarction, stroke, and cardiac arrest.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4056176
- Application Number
- EP22171033A
- Filing Date
- Apr 22, 2019
- Status
- Granted And Under Opposition
- Mar 22, 2024
- Publication Date
- Apr 24, 2024
- External Links
- Slate, Register , Google Patents